Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12268777
Compositions and methods for treating eosinophilic disorders
granted -
US 12268720
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
granted -
US 12268737
Stabilized influenza hemagglutinin stem region trimers and uses thereof
granted -
US 12269805
Inhibitors of platelet function and methods for use of the same
granted -
US 12269860
Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR
granted -
US 12269888
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
granted -
US 12269897
Anti-PCSK9 antibodies
granted -
US 12268831
Swallowable drug delivery device and methods of drug delivery
granted -
US 12268700
3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof
granted -
US 12268673
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 12268678
Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12275964
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
granted -
US 12275966
Genetically engineered cells
granted -
US 12275937
Stereospecific linkages in RNA editing oligonucleotides
granted -
US 12275957
Next generation designer liver organoids and their methods of preparation and use
granted -
US 12275955
Combining iPSC derived effector cell types for immunotherapy use
granted -
US 12275940
Conjugated antisense compounds and their use
granted -
US 12275684
Methods for making and using endoxifen
granted -
US 12275781
Monoclonal antibodies against MHC-bound human dickkopf-1 peptides and uses thereof
granted -
US 12275769
Activatable interleukin 12 polypeptides and methods of use thereof
granted -
US 12274735
IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
granted -
US 12274710
Compound for regulating body weight imbalance, composition thereof and application thereof
granted -
US 12274725
Zika virus strains for treatment of glioma
granted -
US 12275758
Prefusion RSV F proteins and their use
granted -
US 12274759
Affibody proteins specific for B7-H3 (CD276)
granted -
US 12275685
Oligo-benzamide analogs and their use in cancer treatment
granted -
US 12274741
Cattle fever tick-infestation vaccines and uses thereof
granted -
US 12275792
Antigen-binding proteins that activate the leptin receptor
granted -
US 12274684
Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
granted -
US 12274747
Compositions and methods for treating cytokine release syndrome
granted -
US 12275786
Anti-thyroglobulin t cell receptors
granted -
US 12274696
Methods of administering nalbuphine
granted -
US 12274723
Bacteriophage compositions and methods for treatment of bacterial infections
granted -
US 12275788
Single-domain antibodies against CD33 and constructs thereof
granted -
TW 202515903
Anti-PD-1-based treatment before and after surgery
granted -
TW 202515875
Solid forms comprising a B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor
granted -
US 2025120959
NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE
granted -
WO 2025078995
COMPOSÉS DE 6-(PYRIMIDIN-4-YL)QUINOLÉINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASE DÉPENDANTE DE LA CYCLINE
granted -
WO 2025077836
LIPIDES IONISABLES ET NANOPARTICULES LIPIDIQUES POUR ADMINISTRATION D'ARN
granted -
US 12281327
Lymphohematopoietic engineering using CAS9 base editors
granted -
US 12281321
Frataxin expression constructs having engineered promoters and methods of use thereof
granted -
US 12281310
Use of trinucleotide repeat RNAs to treat cancer
granted -
US 12281173
Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor
granted -
US 12281164
Genetically engineered dual-targeting chimeric antigen receptor and use thereof
granted -
US 12281140
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
granted -
US 12281105
Contraceptive compounds and methods
granted -
US 12281122
PI3K inhibitors
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.